Parrish Capital LLC Sells 20,003 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Parrish Capital LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 20.6% during the second quarter, HoldingsChannel reports. The fund owned 77,150 shares of the company’s stock after selling 20,003 shares during the quarter. Teva Pharmaceutical Industries comprises about 2.1% of Parrish Capital LLC’s portfolio, making the stock its 8th largest holding. Parrish Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $2,614,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. California State Teachers Retirement System raised its stake in shares of Teva Pharmaceutical Industries by 3,376.3% during the second quarter. California State Teachers Retirement System now owns 43,270,486 shares of the company’s stock valued at $1,466,004,000 after acquiring an additional 42,025,742 shares during the last quarter. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $1,098,060,000. WCM Investment Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. Wellington Management Group LLP increased its holdings in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of several recent research reports. Barclays lifted their target price on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 21st. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.89.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares in the company, valued at approximately $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.54% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $36.36 on Monday. The firm has a market cap of $42.37 billion, a price-to-earnings ratio of 60.60, a PEG ratio of 4.53 and a beta of 0.87. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a 12-month low of $18.21 and a 12-month high of $38.37. The company’s fifty day simple moving average is $34.64 and its 200 day simple moving average is $33.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The firm had revenue of $4.14 billion during the quarter. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.